Cesalatamig Shows 33% Response in Lung Cancer
OncoC4's Phase 1/2 pooled analysis reports early activity and tolerability of cesalatamig monotherapy in previously treated non-small cell lung cancer.
Updated on Nov. 6, 2026 in Cancer
OncoC4 reported Phase 1/2 results for cesalatamig monotherapy in 103 patients with previously treated non-small cell lung cancer, finding it well tolerated at all dose levels. Among 55 efficacy-evaluable patients, the objective response rate at 10 mg/kg every three weeks was 33%.
Why it matters
Non-small cell lung cancer that progresses after immunotherapy and platinum-based chemotherapy has limited treatment options, and the results add early clinical data for a newer agent in this setting. The U.S. FDA granted cesalatamig Fast Track designation for this indication in September 2026.
The pooled Phase 1/2 analysis of 103 patients reported a 33% objective response rate and 90% disease control rate at 10 mg/kg every three weeks among 55 efficacy-evaluable patients, compared with a 10% response rate at the 1 mg/kg dose. The small sample size and open-label design mean larger, controlled studies are needed to confirm these figures.
The players
OncoC4
OncoC4 is a Rockville, Maryland-based biopharmaceutical company developing cesalatamig, a bispecific antibody candidate for cancer.
U.S. Food and Drug Administration
The FDA is the U.S. federal agency responsible for regulating drugs, and it granted cesalatamig Fast Track designation for this lung cancer indication.
The details
Patients in the global, multicenter BiPAVE-001 and BiPAVE-001 CN studies received cesalatamig monotherapy at 1, 3, 10 or 20 mg/kg every three weeks. Of the 103 safety-population patients, 77 had non-squamous and 25 had squamous histology, with a median of two prior therapy lines.
Timeline
September 2026: U.S. FDA granted cesalatamig Fast Track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.
July 31, 2026: Data cutoff for the safety population analysis.
November 6, 2026: OncoC4 publicly reported the Phase 1/2 results.
November 7, 2026: Late-breaking oral presentation at the SITC 2026 Annual Meeting in Phoenix.
Health Landscape
The FDA's Fast Track designation program is meant to speed development of drugs for serious conditions with unmet need, and cesalatamig's designation for lung cancer after immunotherapy and chemotherapy places this bispecific antibody within that pathway. Its early Phase 1/2 data arrive as researchers seek options for patients whose disease has progressed after standard treatments.
For people with non-small cell lung cancer whose disease has progressed after immunotherapy and platinum-based chemotherapy, these results point to a possible new treatment option still in early development. Patients should discuss any investigational trial or therapy with their oncologist, as availability and eligibility are not established by these early results.
The takeaway
Early data suggest cesalatamig may offer activity in previously treated lung cancer, but its benefit remains unproven until larger pivotal studies report. Readers should treat these findings as preliminary and rely on their care team for current treatment decisions.
What happens next
The late-breaking oral presentation of the Phase 1/2 results is scheduled for November 7, 2026, at the SITC 2026 Annual Meeting in Phoenix, and the 10 mg/kg every-three-weeks dose is planned for a pivotal study.
Further reading
Explore more on Cancer research and treatment developments.
